vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Employers Holdings, Inc. (EIG). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $170.5M, roughly 1.1× Employers Holdings, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -21.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -11.4%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Employers Holdings, Inc. is a U.S.-headquartered insurance holding company that specializes in offering workers' compensation insurance and customized risk management services primarily for small and medium-sized enterprises across the United States. It mainly serves clients in low-to-medium hazard industries, helping them mitigate workplace safety risks and meet relevant regulatory requirements for employee protection.
AXSM vs EIG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $170.5M |
| Net Profit | $-28.6M | — |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | — |
| Revenue YoY | 65.0% | -21.3% |
| Net Profit YoY | 61.9% | — |
| EPS (diluted) | $-0.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $170.5M | ||
| Q4 25 | $196.0M | $188.5M | ||
| Q3 25 | $171.0M | $239.3M | ||
| Q2 25 | $150.0M | $246.3M | ||
| Q1 25 | $121.5M | $202.6M | ||
| Q4 24 | $118.8M | $216.6M | ||
| Q3 24 | $104.8M | $224.0M | ||
| Q2 24 | $87.2M | $217.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-8.3M | ||
| Q2 25 | $-48.0M | $29.7M | ||
| Q1 25 | $-59.4M | $12.8M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $30.3M | ||
| Q2 24 | $-79.3M | $31.7M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | -4.7% | ||
| Q2 25 | -24.5% | 15.0% | ||
| Q1 25 | -46.9% | 7.8% | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | 16.4% | ||
| Q2 24 | -89.5% | 18.4% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -3.5% | ||
| Q2 25 | -32.0% | 12.1% | ||
| Q1 25 | -48.9% | 6.3% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 13.5% | ||
| Q2 24 | -91.0% | 14.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-0.93 | ||
| Q3 25 | $-0.94 | $-0.36 | ||
| Q2 25 | $-0.97 | $1.23 | ||
| Q1 25 | $-1.22 | $0.52 | ||
| Q4 24 | $-1.54 | $1.14 | ||
| Q3 24 | $-1.34 | $1.21 | ||
| Q2 24 | $-1.67 | $1.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $169.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $955.7M |
| Total Assets | $689.8M | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $169.9M | ||
| Q4 25 | $322.9M | $169.9M | ||
| Q3 25 | $325.3M | $172.4M | ||
| Q2 25 | $303.0M | $78.1M | ||
| Q1 25 | $300.9M | $100.4M | ||
| Q4 24 | $315.4M | $68.4M | ||
| Q3 24 | $327.3M | $173.9M | ||
| Q2 24 | $315.7M | $126.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $19.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $955.7M | ||
| Q4 25 | $88.3M | $955.7M | ||
| Q3 25 | $73.7M | $1.0B | ||
| Q2 25 | $73.1M | $1.1B | ||
| Q1 25 | $53.2M | $1.1B | ||
| Q4 24 | $57.0M | $1.1B | ||
| Q3 24 | $92.9M | $1.1B | ||
| Q2 24 | $102.9M | $1.0B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $689.8M | $3.4B | ||
| Q3 25 | $669.3M | $3.5B | ||
| Q2 25 | $639.8M | $3.5B | ||
| Q1 25 | $596.7M | $3.6B | ||
| Q4 24 | $568.5M | $3.5B | ||
| Q3 24 | $561.5M | $3.6B | ||
| Q2 24 | $548.2M | $3.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $44.7M | ||
| Q3 25 | $1.0M | $29.4M | ||
| Q2 25 | $-32.4M | $0 | ||
| Q1 25 | $-43.4M | $14.6M | ||
| Q4 24 | $-26.2M | $76.4M | ||
| Q3 24 | $-18.6M | $51.0M | ||
| Q2 24 | $-30.1M | $11.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $44.6M | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | $76.3M | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 23.7% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | 35.2% | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 1.14× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.68× | ||
| Q2 24 | — | 0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
